TO The, Importing Department Pharmaceutical Import Profile — Italy (DGFT 2022–2026)

Name: TO The, Importing Department Pharmaceutical Import Records from India — 2 Products, $15.2K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

TO The, Importing Department — Pharmaceutical Importer Profile (2026) | 2 Products, $15.2K Trade | TransData Nexus

TO The, Importing Department

Pharmaceutical Importer · Italy · Advanced Oncology Focus · $15.2K Total Trade · DGFT Verified

TO The, Importing Department is a pharmaceutical importer based in Italy with a total trade value of $15.2K across 2 products in 1 therapeutic categories. Based on 42 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. TO The, Importing Department sources from 1 verified Indian supplier, with Jpc Global accounting for 100.0% of imports.

TO The, Importing Department — Import Portfolio & Supplier Network

TO The, Importing Department import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to TO The, Importing Department?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Jpc Global	$888.3K	518	100.0%

TO The, Importing Department sources from 1 verified Indian supplier across 234 distinct formulations. The sourcing is highly concentrated — Jpc Global accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does TO The, Importing Department Import?

Formulation	Value	Ships
Hpfp - eptifibatide 75MG/100ML INJ - mfg: united biotech (p) limited - (mfg gstno:07aaacu1839l1z4	$100.0K	2
Harmless pharmaceutical finished product- aztreonam for INJ USP 1000MG/1GM	$62.6K	26
H p f p - micafungin sodium 100MG for INJ - mfg: united biotech (p) limited - (mfg gst no: 07aaacu1839l1z4)	$50.0K	1
Harmless pharmaceutical finished product- oseltamivir 75MG CAPS - pcs(10s)	$41.4K	2
Hpfp - eptifibatide 20MG/10ML INJ - mfg:united biotech (p) limited - (mfg gst no:07aaacu1839l1z4	$35.0K	1
Hpfp - eptifibatide 20MG/10ML INJ- mfg:united biotech (p) limited - (mfg gst no:07aaacu1839l1z4	$34.9K	1
Harmless pharmaceutical finished product- sodium nitroprusside 50MG INJ	$30.2K	24
Harmless pharmaceutical finished product aztreonam for INJ USP 1000MG/1GM	$25.4K	12
Hpfp-tenofovir disoproxil fumarate 300mgequivalent to tenofovir disoproxil 245MG & emtricitabine 200MG tabs-pcs(30s)	$22.6K	1
Harmless pharmaceutical finished product- phytomenadione 0.2ML INJ for i.m/i.v./ oral use - pcs(10s)	$21.8K	1
Harmless pharmaceutical finished product-palbosiclib CAPS 125MG - pcs(21s)	$20.5K	2
Harmless pharmaceutical finished product- indocyanine green INJ 25MG	$20.3K	8
Harmless pharmaceutical finished product phytomenadione 0.2ML INJ for i.m/i.v./ oral use - pcs(10s)	$18.4K	1
Harmless pharmaceutical finished product- interferon alpha 2b INJ IP 0.5ML/3miu	$15.8K	3
Harmless pharmaceutical finished product sodium nitroprusside 50MG INJ	$15.7K	10

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Tofacitinib	Advanced Oncology	$10.4K	14	0.3%	13
2	Lomustine	Advanced Oncology	$4.8K	28	2.5%	3

TO The, Importing Department imports 2 pharmaceutical products across 1 categories into Italy totaling $15.2K.

TO The, Importing Department — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

TO The, Importing Department is a pharmaceutical importer based in Italy, specializing in the procurement of finished pharmaceutical formulations. The company operates as an independent entity, focusing on sourcing and importing pharmaceutical products to meet the needs of the Italian market. While specific details about its parent company are not publicly available, TO The plays a significant role in Italy's pharmaceutical distribution network by ensuring the availability of essential medications.

2Distribution Network

TO The's distribution network encompasses multiple warehouse locations strategically situated across Italy to facilitate efficient logistics and timely delivery of pharmaceutical products. The company's logistics capabilities are robust, enabling it to manage a diverse portfolio of imported medications. Geographically, TO The's coverage extends throughout Italy, ensuring nationwide access to its imported pharmaceutical products.

3Industry Role

In Italy's pharmaceutical supply chain, TO The, Importing Department functions primarily as a pharmaceutical importer. The company sources finished pharmaceutical formulations from international suppliers, including India, and distributes them within the Italian market. This role is crucial in ensuring the availability of a wide range of medications to meet the therapeutic needs of the population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — TO The, Importing Department

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

TO The's sourcing strategy exhibits a high degree of concentration, with a total import value of $15,000 USD from India over 42 shipments, primarily consisting of two products: Tofacitinib and Lomustine. This single-source dependency may pose risks related to supply chain disruptions, such as potential delays or shortages. The consistent shipment data suggests a stable relationship with the supplier, JPC GLOBAL, which has provided 100% of the imported products. However, the lack of diversification in sourcing could impact the company's ability to respond to market fluctuations or supply chain challenges.

2Supply Chain Resilience

The resilience of TO The's supply chain is closely tied to its exclusive reliance on JPC GLOBAL for sourcing finished pharmaceutical formulations from India. The absence of backup suppliers and limited formulation diversity may expose the company to risks associated with supply chain disruptions. Additionally, the company's exposure to specific shipping routes and potential regulatory changes in India could further impact supply chain stability. Ensuring compliance with regulatory standards and maintaining a diversified supplier base are essential steps to enhance supply chain resilience.

Strategic Implications

Importing Pharmaceuticals into Italy — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Italy

1Regulatory Authority & Framework

In Italy, the Italian Medicines Agency (AIFA) serves as the national authority responsible for regulating pharmaceutical products. Key legislation governing pharmaceutical imports includes Legislative Decree 219/2006, which outlines the procedures for marketing authorization and importation of medicinal products. The marketing authorization pathway for Indian generics involves obtaining approval from AIFA, ensuring compliance with European Union standards, and meeting specific requirements set forth by the agency.

2Import Licensing & GMP

Import licensing requirements in Italy stipulate that pharmaceutical importers must hold a valid Manufacturing and Import Authorization (MIA) license issued by AIFA. Additionally, imported pharmaceutical products must comply with Good Manufacturing Practice (GMP) standards recognized by the European Union, WHO, or PIC/S. Wholesale distribution authorization is also mandatory for entities involved in the distribution of pharmaceutical products within Italy.

3Quality & Labeling

TO The, Importing Department — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

TO The's product category focus on advanced oncology reflects a strategic decision to address the growing demand for cancer treatments in Italy. The imports of Tofacitinib and Lomustine indicate a targeted approach to providing essential medications for oncology patients. Market demand for these products is driven by the increasing prevalence of cancer and the need for effective therapeutic options.

2Sourcing Profile

TO The's sourcing strategy emphasizes the procurement of generic drugs, particularly in the oncology therapeutic area. The company's preference for specific formulations aligns with its focus on providing targeted treatments to the Italian market. India's established pharmaceutical manufacturing capabilities make it a suitable partner for sourcing these formulations.

3Market Positioning

Based on its product mix, TO The, Importing Department serves the hospital segment of the Italian market. By supplying specialized oncology medications, the company supports hospitals in delivering advanced cancer treatments to patients. This positioning underscores TO The's role in enhancing the quality of healthcare services within Italy.

Seller's Guide — How to Become a Supplier to TO The, Importing Department

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with TO The by offering high-quality generic oncology medications that meet the company's specific requirements. Gaps in TO The's current sourcing include a limited product portfolio and reliance on a single supplier. Indian exporters can address these gaps by providing a diversified range of formulations and ensuring consistent supply to strengthen the partnership.

2Requirements & Qualifications

Indian exporters seeking to supply TO The must obtain the necessary certifications and regulatory approvals, including GMP compliance recognized by the European Union, WHO, or PIC/S. Products must meet AIFA's quality standards, and exporters should be prepared to navigate the import licensing process to ensure successful market entry.

3How to Approach

To establish a relationship with TO The, Indian exporters should initiate contact to understand the company's specific product requirements and quality standards. Participating in relevant tenders and aligning with AIFA's regulatory filing strategies are essential steps. Understanding the import licensing process and adhering to timelines will facilitate a smooth entry into the Italian market.

Frequently Asked Questions — TO The, Importing Department

What products does TO The, Importing Department import from India?

TO The, Importing Department imports 2 pharmaceutical products across 1 categories. Top imports: Tofacitinib ($10.4K), Lomustine ($4.8K).

Who supplies pharmaceuticals to TO The, Importing Department from India?

TO The, Importing Department sources from 1 verified Indian suppliers. The primary supplier is Jpc Global (100.0% of imports, $888.3K).

What is TO The, Importing Department's total pharmaceutical import value?

TO The, Importing Department's total pharmaceutical import value from India is $15.2K, based on 42 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does TO The, Importing Department focus on?

TO The, Importing Department imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full TO The, Importing Department Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.